Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Head and Neck Cancer

  Free Subscription


Articles published in Clin Cancer Res

Retrieve available abstracts of 48 articles:
HTML format
Text format



Single Articles


    April 2017
  1. LUDWIG S, Floros T, Theodoraki MN, Hong CS, et al
    Suppression of lymphocyte functions by plasma exosomes correlates with disease activity in patients with head and neck cancer.
    Clin Cancer Res. 2017 Apr 11. pii: clincanres.2819.2016.
    PubMed     Text format     Abstract available


    March 2017
  2. ZHANG S, Zhang B, Tian J, Dong D, et al
    Radiomics features of Multiparametric MRI as Novel Prognostic Factors in Advanced Nasopharyngeal Carcinoma.
    Clin Cancer Res. 2017 Mar 9. pii: clincanres.2910.2016.
    PubMed     Text format     Abstract available


    February 2017
  3. HSU DS, Hwang WL, Yuh CH, Chu CH, et al
    Lymphotoxin-beta interacts with methylated EGFR to mediate acquired resistance to cetuximab in head and neck cancer.
    Clin Cancer Res. 2017 Feb 14. pii: clincanres.1955.2016.
    PubMed     Text format     Abstract available


    December 2016
  4. BRAND TM, Hartmann S, Bhola NE, Peyser ND, et al
    Human papillomavirus regulates HER3 expression in head and neck cancer: implications for targeted HER3 therapy in HPV(+) patients.
    Clin Cancer Res. 2016 Dec 16. pii: clincanres.2203.2016.
    PubMed     Text format     Abstract available


  5. MUHAMMAD N, Bhattacharya S, Steele R, Phillips NJ, et al
    Involvement of c-Fos in the promotion of cancer stem-like cell properties in head and neck squamous cell carcinoma.
    Clin Cancer Res. 2016 Dec 13. pii: clincanres.2811.2016.
    PubMed     Text format     Abstract available


    October 2016
  6. KERK S, Finkel K, Pearson AT, Warner K, et al
    5T4-targeted therapy ablates cancer stem cells and prevents recurrence of head and neck squamous cell carcinoma.
    Clin Cancer Res. 2016 Oct 25. pii: clincanres.1834.2016.
    PubMed     Text format     Abstract available


  7. YAMAMURA K, Baba Y, Nakagawa S, Mima K, et al
    Human Microbiome Fusobacterium Nucleatum in Esophageal Cancer Tissue Is Associated with Prognosis.
    Clin Cancer Res. 2016.
    PubMed     Text format     Abstract available


    September 2016
  8. MANCIKOVA V, Montero-Conde C, Perales-Paton J, Fernandez AF, et al
    Multilayer OMIC data in medullary thyroid carcinoma identifies the STAT3 pathway as a potential therapeutic target in RETM918T tumors.
    Clin Cancer Res. 2016 Sep 12. pii: clincanres.0947.2016.
    PubMed     Text format     Abstract available


    August 2016
  9. SRIVASTAVA RM, Trivedi S, Concha-Benavente F, Gibson SP, et al
    CD137 stimulation enhances cetuximab induced natural killer (NK): dendritic cell (DC) priming of anti-tumor T cell immunity in head and neck cancer patients.
    Clin Cancer Res. 2016 Aug 5. pii: clincanres.0879.2016.
    PubMed     Text format     Abstract available


    July 2016
  10. ZHANG JX, Chen ZH, Xu Y, Chen JW, et al
    Downregulation of MicroRNA-644a Promotes Esophageal Squamous Cell Carcinoma Aggressiveness and Stem-cell-like Phenotype via Dysregulation of PITX2.
    Clin Cancer Res. 2016 Jul 12. pii: clincanres.0414.2016.
    PubMed     Text format     Abstract available


  11. HARTMANN S, Bhola NE, Grandis JR
    HGF/Met Signaling in Head and Neck Cancer: Impact on the Tumor Microenvironment.
    Clin Cancer Res. 2016 Jul 1. pii: clincanres.0951.2016.
    PubMed     Text format     Abstract available


    June 2016

  12. Correction: Pretreatment microRNA Expression Impacting on Epithelial-to-Mesenchymal Transition Predicts Intrinsic Radiosensitivity in Head and Neck Cancer Cell Lines and Patients.
    Clin Cancer Res. 2016;22:3118.
    PubMed     Text format    


    May 2016
  13. TRIVEDI S, Srivastava RM, Concha-Benavente F, Ferrone S, et al
    Anti-EGFR targeted monoclonal antibody isotype influences anti-tumor cellular immunity in head and neck cancer patients.
    Clin Cancer Res. 2016 May 23. pii: clincanres.2971.2015.
    PubMed     Text format     Abstract available


    April 2016
  14. CHAU NG, Hammerman PS
    Heads Up! Predictive Gene Signatures in Head and Neck Cancer May Be Coming Soon.
    Clin Cancer Res. 2016 Apr 29. pii: clincanres.0582.2016.
    PubMed     Text format     Abstract available


  15. ZHANG Y, Koneva LA, Virani S, Arthur AE, et al
    Subtypes of HPV-positive head and neck cancers are associated with HPV characteristics, copy number alterations, PIK3CA mutation, and pathway signatures.
    Clin Cancer Res. 2016 Apr 18. pii: clincanres.0323.2016.
    PubMed     Text format     Abstract available


  16. ZUMSTEG ZS, Morse N, Krigsfeld G, Gupta G, et al
    Taselisib (GDC-0032), a Potent beta-Sparing Small Molecule Inhibitor of PI3K, Radiosensitizes Head and Neck Squamous Carcinomas Containing Activating PIK3CA Alterations.
    Clin Cancer Res. 2016;22:2009-19.
    PubMed     Text format     Abstract available


  17. SKINNER HD, Giri U, Yang L, Woo SH, et al
    Proteomic profiling identifies PTK2/FAK as a driver of radioresistance in HPV negative head and neck cancer.
    Clin Cancer Res. 2016 Apr 1. pii: clincanres.2785.2015.
    PubMed     Text format     Abstract available


  18. GRANDIS J
    HER2 and HER3 in HPV+ and HPV- HNSCC--Response.
    Clin Cancer Res. 2016;22:1826.
    PubMed     Text format    


  19. MACHIELS JP, Galot R, Schmitz S
    HER2 and HER3 in HPV+ and HPV- HNSCC--Letter.
    Clin Cancer Res. 2016;22:1825.
    PubMed     Text format    


    March 2016
  20. CHEN P, Hu T, Liang Y, Li P, et al
    Neddylation Inhibition Activates the Extrinsic Apoptosis Pathway through ATF4-CHOP-DR5 Axis in Human Esophageal Cancer Cells.
    Clin Cancer Res. 2016 Mar 16. pii: clincanres.2254.2015.
    PubMed     Text format     Abstract available


  21. KOOLE K, Brunen D, van Kempen PM, Noorlag R, et al
    FGFR1 is a potential prognostic biomarker and therapeutic target in head and neck squamous cell carcinoma.
    Clin Cancer Res. 2016 Mar 2. pii: clincanres.1874.2015.
    PubMed     Text format     Abstract available


    February 2016
  22. COGHILL AE, Bu W, Nguyen H, Hsu WL, et al
    High levels of antibody that neutralize B-cell infection of Epstein-Barr virus and that bind EBV gp350 are associated with a lower risk of nasopharyngeal carcinoma.
    Clin Cancer Res. 2016 Feb 26. pii: clincanres.2299.2015.
    PubMed     Text format     Abstract available


  23. LEE Y, Shin JH, Longmire M, Wang H, et al
    CD44+ cells in head and neck squamous cell carcinoma suppress T cell-mediated immunity by selective constitutive and inducible expression of PD-L1.
    Clin Cancer Res. 2016 Feb 10. pii: clincanres.2665.2015.
    PubMed     Text format     Abstract available


  24. MITANI Y, Liu B, Rao PH, Borra VJ, et al
    Novel MYBL1 Gene Rearrangements with Recurrent MYBL1-NFIB Fusions in Salivary Adenoid Cystic Carcinomas Lacking t(6;9) Translocations.
    Clin Cancer Res. 2016;22:725-33.
    PubMed     Text format     Abstract available


  25. VASSILAKOPOULOU M, Avgeris M, Velcheti V, Kotoula V, et al
    Evaluation of PD-L1 Expression and Associated Tumor-Infiltrating Lymphocytes in Laryngeal Squamous Cell Carcinoma.
    Clin Cancer Res. 2016;22:704-13.
    PubMed     Text format     Abstract available


    January 2016
  26. CHAU NG, Li YY, Jo VY, Rabinowits G, et al
    Incorporation of next-generation sequencing into routine clinical care to direct treatment of head and neck squamous cell carcinoma.
    Clin Cancer Res. 2016 Jan 13. pii: clincanres.2314.2015.
    PubMed     Text format     Abstract available


    December 2015
  27. ROTHENBERG SM, Daniels GH, Wirth LJ
    Redifferentiation of Iodine-Refractory BRAF V600E-Mutant Metastatic Papillary Thyroid Cancer with Dabrafenib-Response.
    Clin Cancer Res. 2015;21:5640-5641.
    PubMed     Text format    


  28. HUILLARD O, Tenenbaum F, Clerc J, Goldwasser F, et al
    Redifferentiation of Iodine-Refractory BRAF V600E-Mutant Metastatic Papillary Thyroid Cancer with Dabrafenib-Letter.
    Clin Cancer Res. 2015;21:5639.
    PubMed     Text format    


    November 2015
  29. ROMICK-ROSENDALE LE, Hoskins EE, Privette Vinnedge LM, Foglesong GD, et al
    Defects in the Fanconi anemia pathway in head and neck cancer cells stimulate tumor cell invasion through DNA-PK and Rac1 signaling.
    Clin Cancer Res. 2015 Nov 24. pii: clincanres.2209.2015.
    PubMed     Text format     Abstract available


    October 2015
  30. SWIERNIAK M, Wojcicka A, Czetwertynska M, Dlugosinska J, et al
    Association Between GWAS-derived rs966423 Genetic Variant and Overall Mortality in Patients with Differentiated Thyroid Cancer.
    Clin Cancer Res. 2015 Oct 21. pii: clincanres.1746.2015.
    PubMed     Text format     Abstract available


  31. YEUNG KT, Cohen EE
    Lenvatinib in Advanced, Radioactive Iodine-Refractory, Differentiated Thyroid Carcinoma.
    Clin Cancer Res. 2015 Oct 20. pii: clincanres.0923.2015.
    PubMed     Text format     Abstract available


  32. LI B, Xu WW, Guan X, Qin YR, et al
    Competitive binding between Id1 and E2F1 to Cdc20 regulates E2F1 degradation and thymidylate synthase expression to promote esophageal cancer chemoresistance.
    Clin Cancer Res. 2015 Oct 16. pii: clincanres.1196.2015.
    PubMed     Text format     Abstract available


  33. MUHANNA N, Cui L, Chan H, Burgess L, et al
    Multimodal Image-Guided Surgical and Photodynamic Interventions in Head-and-Neck Cancer: From Primary Tumor to Metastatic Drainage.
    Clin Cancer Res. 2015 Oct 13. pii: clincanres.1235.2015.
    PubMed     Text format     Abstract available


    September 2015
  34. FRANCIS DM, Huang S, Armstrong EA, Werner LR, et al
    Pan-HER receptor inhibition augments radiation response in human lung and head and neck cancer models.
    Clin Cancer Res. 2015 Sep 29. pii: clincanres.1664.2015.
    PubMed     Text format     Abstract available


  35. ZHANG HF, Chen Y, Wu C, Wu Z, et al
    The opposing function of STAT3 as an oncoprotein and tumor suppressor is dictated by the expression status of STAT3beta in esophageal squamous cell carcinoma.
    Clin Cancer Res. 2015 Sep 24. pii: clincanres.1253.2015.
    PubMed     Text format     Abstract available


    August 2015
  36. NAIR A, Lemery SJ, Yang J, Marathe A, et al
    FDA Approval Summary: Lenvatinib for Progressive, Radio-iodine-Refractory Differentiated Thyroid Cancer.
    Clin Cancer Res. 2015 Aug 31. pii: clincanres.1377.2015.
    PubMed     Text format     Abstract available


  37. SCHLUMBERGER M, Jarzab B, Cabanillas ME, Robinson BG, et al
    A Phase 2 Trial of the Multi-targeted Tyrosine Kinase Inhibitor Lenvatinib (E7080) in Advanced Medullary Thyroid Cancer (MTC).
    Clin Cancer Res. 2015 Aug 26. pii: clincanres.1127.2015.
    PubMed     Text format     Abstract available


  38. DE JONG MC, Ten Hoeve J, Grenman R, Wessels L, et al
    Pretreatment microRNA expression impacting on epithelial to mesenchymal transition predicts intrinsic radiosensitivity in head and neck cancer celllines and patients.
    Clin Cancer Res. 2015 Aug 11. pii: clincanres.0454.2015.
    PubMed     Text format     Abstract available


    July 2015

  39. Correction: A Phase II Study of Pazopanib in Asian Patients with Recurrent/Metastatic Nasopharyngeal Carcinoma.
    Clin Cancer Res. 2015;21:3358.
    PubMed     Text format    


    June 2015
  40. CASAK SJ, Fashoyin-Aje I, Lemery SJ, Zhang L, et al
    FDA Approval Summary: Ramucirumab for Gastric Cancer.
    Clin Cancer Res. 2015 Jun 5. pii: clincanres.0600.2015.
    PubMed     Text format     Abstract available


  41. JURIC D, Dienstmann R, Cervantes A, Hidalgo M, et al
    Safety and Pharmacokinetics/Pharmacodynamics of the First-in-Class Dual Action HER3/EGFR Antibody MEHD7945A in Locally Advanced or Metastatic Epithelial Tumors.
    Clin Cancer Res. 2015;21:2462-70.
    PubMed     Text format     Abstract available


    May 2015
  42. MOHAN S, Vander Broek R, Shah S, Eytan DF, et al
    MEK inhibitor PD-0325901 overcomes resistance to PI3K/mTOR inhibitor PF-5212384 and potentiates anti-tumor effects in human head and neck squamous cell carcinoma.
    Clin Cancer Res. 2015 May 14. pii: clincanres.3377.2015.
    PubMed     Text format     Abstract available


  43. MEHTA A, Zhang L, Boufraqech M, Liu-Chittenden Y, et al
    Inhibition of survivin with YM155 induces durable tumor response in anaplastic thyroid cancer.
    Clin Cancer Res. 2015 May 5. pii: clincanres.3251.2014.
    PubMed     Text format     Abstract available


    April 2015
  44. MACDONALD AJ, Johns N, Stephens N, Greig C, et al
    Habitual Myofibrillar Protein Synthesis Is Normal in Patients with Upper GI Cancer Cachexia.
    Clin Cancer Res. 2015;21:1734-40.
    PubMed     Text format     Abstract available


    February 2015
  45. KIM HS, Kwon HJ, Jung I, Yun MR, et al
    Phase II clinical and exploratory biomarker study of dacomitinib in patients with recurrent and/or metastatic squamous cell carcinoma of head and neck.
    Clin Cancer Res. 2015;21:544-52.
    PubMed     Text format     Abstract available


    December 2014
  46. ROTHENBERG SM, McFadden DG, Palmer EL, Daniels GH, et al
    Redifferentiation of iodine-refractory BRAF V600E-mutant metastatic papillary thyroid cancer with dabrafenib.
    Clin Cancer Res. 2014 Dec 30. pii: clincanres.2915.2014.
    PubMed     Text format     Abstract available


    October 2014
  47. ANGELL TE, Lechner MG, Jang JK, LoPresti JS, et al
    MHC Class I Loss is a Frequent Mechanism of Immune Escape in Papillary Thyroid Cancer that is Reversed by Interferon and Selumetinib Treatment in vitro.
    Clin Cancer Res. 2014 Oct 7. pii: clincanres.0879.2014.
    PubMed     Text format     Abstract available


    May 2014
  48. RICCARDO F, Iussich S, Maniscalco L, Lorda-Mayayo S, et al
    CSPG4-specific immunity and survival prolongation in dogs with oral malignant melanoma immunized with human CSPG4 DNA.
    Clin Cancer Res. 2014 May 29. pii: clincanres.3042.2013.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Head and Neck Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: